Use of dong qual (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer:: is it appropriate?

被引:27
|
作者
Lau, CBS [1 ]
Ho, TCY [1 ]
Chan, TWL [1 ]
Kim, SCF [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2005年 / 12卷 / 06期
关键词
Angelica sinensis; dong quai; breast cancer; estrogen receptor; menopause; herbal therapy;
D O I
10.1097/01.gme.0000184419.65943.01
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Regarding the growing use of alternative therapies for peri- or postmenopausal symptoms, we evaluated the effect of a water extract of Angelica sinensis (dong qual), used for peri- or postmenopausal relief, on the proliferation of estrogen receptor-positive (MCF-7) and negative (BT-20) breast cancer cells in vitro. Design: The present study was designed to investigate the growth-modulating effect of dong quai water extract, alone or in the presence of 17 beta-estradiol and 4-hydroxytamoxifen, on MCF-7 and BT-20 cell cultures using MTT proliferation assay. Results: The water extract of dong quai dose-dependently and significantly stimulated the proliferation of MCF-7 cells with a weak estrogen-agonistic activity in the presence of 17 beta-estradiol, as evidenced by the significant suppression by 4-hydroxytamoxifen. Meanwhile, the extract significantly exerted a growth-stimulating effect on BT-20 in a dose-dependent manner with or without 17 beta-estradiol. No obvious difference was found in the growth of BT-20 cells treated with the extract in the presence of 17 beta-estradiol or 4-hydroxytamoxifen. Conclusions: The water extract of dong quai stimulated the growth of MCF-7 cells, possibly dependent of weak estrogen-agonistic activity, and augmented the BT-20 cell proliferation independent of estrogen receptor-mediated pathway. The present study provides data regarding the estrogen-like activity of dong quai, which might assist in decision making on herbal therapy use by women at risk for both estrogen-sensitive and insensitive breast cancer. Because of the lack of clinical data demonstrating the potential side effects of dong quai, its use in herbal preparations for the treatment of peri- or postmenopausal symptoms, especially in women with breast cancer, warrants caution pending further study.
引用
收藏
页码:734 / 740
页数:7
相关论文
共 50 条
  • [41] Examining the effect of 5-HTTLPR on depressive symptoms in postmenopausal women 1 year after initial breast cancer treatment
    Justine S. Wang
    Yvette P. Conley
    Susan M. Sereika
    Catherine M. Bender
    Poorwa Godbole
    Susan W. Wesmiller
    Supportive Care in Cancer, 2019, 27 : 513 - 519
  • [42] Aromatase Inhibitor-Related Symptoms Reported by Postmenopausal Women with Nonmetastatic, Estrogen Receptor-Positive Breast Cancer: A Systematic Review
    Lund-Jacobsen, Trine
    Bentsen, Line
    Schwarz, Peter
    Knop, Ann Soegaard
    Pappot, Helle
    Piil, Karin
    SEMINARS IN ONCOLOGY NURSING, 2023, 39 (05)
  • [43] Examining the effect of 5-HTTLPR on depressive symptoms in postmenopausal women 1year after initial breast cancer treatment
    Wang, Justine S.
    Conley, Yvette P.
    Sereika, Susan M.
    Bender, Catherine M.
    Godbole, Poorwa
    Wesmiller, Susan W.
    SUPPORTIVE CARE IN CANCER, 2019, 27 (02) : 513 - 519
  • [44] Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters
    Borreani, Claudia
    Alfieri, Sara
    Infante, Gabriele
    Miceli, Rosalba
    Mariani, Paola
    Bosisio, Marco
    Vernieri, Claudio
    Bianchi, Giulia, V
    Capri, Giuseppe
    ONCOLOGY, 2021, 99 (02) : 84 - 95
  • [45] Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative
    Drieling, Rebecca L.
    LaCroix, Andrea Z.
    Beresford, Shirley A. A.
    Boudreau, Denise M.
    Kooperberg, Charles
    Chlebowski, Rowan T.
    Gass, Margery
    Crandall, Carolyn J.
    Womack, Catherine R.
    Heckbert, Susan R.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016, 23 (11): : 1168 - 1175
  • [47] Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study
    Sixten Harborg
    Uffe Heide-Jørgensen
    Thomas P. Ahern
    Marianne Ewertz
    Deirdre Cronin-Fenton
    Signe Borgquist
    Breast Cancer Research and Treatment, 2020, 183 : 153 - 160
  • [48] Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality
    Obiorah, Ifeyinwa
    Jordan, V. Craig
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (04): : 372 - 382
  • [49] FulvestrantA Review of its Use in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression following Antiestrogen Therapy
    Kate McKeage
    Monique P. Curran
    Greg L. Plosker
    Drugs, 2004, 64 : 633 - 648
  • [50] Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study
    Garcia-Sanchez, Javier
    Alejandra Mafla-Espana, Mayra
    Dolores Torregrosa, Maria
    Cauli, Omar
    BREAST, 2022, 66 : 310 - 316